FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD



By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/fda-approves-orca%E2%80%91t-next%E2%80%91gen-hsct-reduce-2026a1000mg2?src=rss

Author :

Publish date : 2026-07-01 15:46:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version